跳至主要内容
临床试验/NCT01012245
NCT01012245已完成不适用

Project "XCHANGE" Non-Interventional Study

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.0 个研究点目标入组 28,812 人开始时间: 2000年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
28,812
主要终点
Change From Baseline in Optic Disc Excavation: Horizontal Cup to Disc Ratio

研究概览

简要总结

Non-interventional study to obtain real life data from the treatment with Xalatan and Xalacom in Germany and to assess the long-term efficacy and tolerability under routine conditions. Data were entered into an electronic case report form.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • patients with ocular hypertension or glaucoma, defined by SmPC

排除标准

  • defined by SmPC

结局指标

主要结局

Change From Baseline in Optic Disc Excavation: Horizontal Cup to Disc Ratio

时间窗: Baseline, 1 year, 2 years, and 3 years

Mean horizontal cup to disc (cup/disc or C/D) ratio to assess the progression of glaucoma; calculated as the ratio of the diameter of the depression (cup) to that of the optical nerve head (disc). If values were given for both right and left eye, the value of the right eye was analyzed. Change calculated as mean of (value of cup/disc ratio at observation minus baseline value).

Change From Baseline in Intraocular Pressure (IOP)

时间窗: Baseline, 1 year, 2 years, and 3 years

Mean IOP values measured by applanation tonometry. Only Goldman values are displayed; if values were given for both right and left eye, the value of the right eye was analyzed. Change (absolute difference) calculated as mean of (value of IOP at observation minus baseline value). Study course is reported by yearly intervals and clustered as 1 year (12±3 months), 2 years (24±3 months), and 3 years (36±3 months).

Aulhorn Stage (Visual Field Defects)

时间窗: Baseline, 1 year, 2 years, and 3 years

Number of subjects at each Aulhorn stage. Staged as: No scotoma; Stage I (relative scotomas only), Stage II (absolute scotomas without connection to the blind spot), Stage III (absolute scotomas with connection to the blind spot), Stage IV (absolute scotomas more than 1 quadrant affected), and Stage V (temporal residual visual field only). If values were given for both right and left eye, the value of the right eye was analyzed.

Change From Baseline in Optic Disc Excavation: Vertical Cup to Disc Ratio

时间窗: Baseline, 1 year, 2 years, and 3 years

Mean vertical cup to disc (cup/disc or C/D) ratio to assess the progression of glaucoma; calculated as the ratio of the diameter of the depression (cup) to that of the optical nerve head (disc). If values were given for both right and left eye, the value of the right eye was analyzed. Change calculated as mean of (value of cup/disc ratio at observation minus baseline value).

次要结局

  • Subject Assessment of Satisfaction With Xalatan® Treatment(Baseline, 1 year, 2 years, and 3 years)
  • Subject Self-care: Application of Eye Drops(Baseline, 1 year, 2 years, and 3 years)
  • Reasons for Discontinuation From Study(January 2000 through December 2008)
  • Changes to the Color of the Iris During Xalatan® or Xalacom® Treatment(Baseline up to 3 years)
  • Investigator Assessment of Xalatan® Efficacy(Baseline, 1 year, 2 years, and 3 years)
  • Visual Acuity (Visus)(Baseline, 1 year, 2 years, and 3 years)
  • Investigator Assessment of Tolerability of Xalatan® Treatment(Baseline up to 3 years)
  • Visual Impairment Due to Glaucoma(Baseline, 1 year, 2 years, and 3 years)
  • Reasons for Changes in Glaucoma Therapy(January 2000 through December 2008)

研究者

发起方
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
申办方类型
Industry
责任方
Sponsor

相似试验